Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Dermatofibrosarcoma
Outcome of patients with primary or recurrent dermatofibrosarcoma protuberans analyzed
January 10th, 2006
The outcome of patients with primary or recurrent dermatofibrosarcoma protuberans (DFSP) was analyzed. "DFSP is a rare, low-grade, cutaneous sarcoma with autocrine overproduction of the platelet-derived growth factor (PDGF) beta-chain from gene rearrangement as a key pathogenetic factor, now susceptible of molecular-targeted therapy. The aim of this retrospective analysis was to explore the outcome of patients with primary or recurrent DFSP. Two hundred eighteen patients surgically treated at the Istituto Nazionale per lo studio e la cura dei Tumori (Milan, Italy) over 20 years were reviewed," scientists in Italy reported. "Local relapse, distant...
Source: Cancer Weekly (2006-01-10)
|
